vs
Metallus Inc.（MTUS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Metallus Inc.的季度营收约是Orthofix Medical Inc.的1.4倍（$308.3M vs $219.9M），Metallus Inc.净利率更高（1.8% vs -1.0%，领先2.8%），Metallus Inc.同比增速更快（9.9% vs 2.0%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.3%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MTUS vs OFIX — 直观对比
营收规模更大
MTUS
是对方的1.4倍
$219.9M
营收增速更快
MTUS
高出7.9%
2.0%
净利率更高
MTUS
高出2.8%
-1.0%
两年增速更快
OFIX
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $308.3M | $219.9M |
| 净利润 | $5.4M | $-2.2M |
| 毛利率 | 8.1% | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 1.8% | -1.0% |
| 营收同比 | 9.9% | 2.0% |
| 净利润同比 | 315.4% | 92.4% |
| 每股收益（稀释后） | $0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTUSOFIX
| Q1 26 | $308.3M | — | ||
| Q4 25 | $267.3M | $219.9M | ||
| Q3 25 | $305.9M | $205.6M | ||
| Q2 25 | $304.6M | $203.1M | ||
| Q1 25 | $280.5M | $193.6M | ||
| Q4 24 | $240.5M | $215.7M | ||
| Q3 24 | $227.2M | $196.6M | ||
| Q2 24 | $294.7M | $198.6M |
净利润MTUSOFIX
| Q1 26 | $5.4M | — | ||
| Q4 25 | $-14.3M | $-2.2M | ||
| Q3 25 | $8.1M | $-22.8M | ||
| Q2 25 | $3.7M | $-14.1M | ||
| Q1 25 | $1.3M | $-53.1M | ||
| Q4 24 | $-21.4M | $-29.1M | ||
| Q3 24 | $-5.9M | $-27.4M | ||
| Q2 24 | $4.6M | $-33.4M |
毛利率MTUSOFIX
| Q1 26 | 8.1% | — | ||
| Q4 25 | 2.2% | 71.1% | ||
| Q3 25 | 11.4% | 72.2% | ||
| Q2 25 | 10.6% | 68.7% | ||
| Q1 25 | 7.8% | 62.8% | ||
| Q4 24 | 4.5% | 69.0% | ||
| Q3 24 | 5.3% | 68.7% | ||
| Q2 24 | 8.2% | 67.8% |
营业利润率MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | -7.7% | 0.2% | ||
| Q3 25 | 3.6% | -8.3% | ||
| Q2 25 | 2.8% | -7.9% | ||
| Q1 25 | 1.0% | -25.2% | ||
| Q4 24 | -10.1% | -5.3% | ||
| Q3 24 | -3.1% | -9.6% | ||
| Q2 24 | 2.1% | -12.5% |
净利率MTUSOFIX
| Q1 26 | 1.8% | — | ||
| Q4 25 | -5.3% | -1.0% | ||
| Q3 25 | 2.6% | -11.1% | ||
| Q2 25 | 1.2% | -6.9% | ||
| Q1 25 | 0.5% | -27.4% | ||
| Q4 24 | -8.9% | -13.5% | ||
| Q3 24 | -2.6% | -13.9% | ||
| Q2 24 | 1.6% | -16.8% |
每股收益（稀释后）MTUSOFIX
| Q1 26 | $0.13 | — | ||
| Q4 25 | $-0.34 | $-0.05 | ||
| Q3 25 | $0.19 | $-0.57 | ||
| Q2 25 | $0.09 | $-0.36 | ||
| Q1 25 | $0.03 | $-1.35 | ||
| Q4 24 | $-0.46 | $-0.76 | ||
| Q3 24 | $-0.13 | $-0.71 | ||
| Q2 24 | $0.10 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $104.0M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $683.0M | $450.0M |
| 总资产 | $1.1B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MTUSOFIX
| Q1 26 | $104.0M | — | ||
| Q4 25 | $156.7M | $82.0M | ||
| Q3 25 | $191.5M | $62.9M | ||
| Q2 25 | $190.8M | $65.6M | ||
| Q1 25 | $180.3M | $58.0M | ||
| Q4 24 | $240.7M | $83.2M | ||
| Q3 24 | $254.6M | $30.1M | ||
| Q2 24 | $272.8M | $26.4M |
总债务MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $0 | $157.2M | ||
| Q2 25 | $0 | $157.0M | ||
| Q1 25 | $5.4M | $156.9M | ||
| Q4 24 | $5.4M | $157.0M | ||
| Q3 24 | $13.2M | $118.5M | ||
| Q2 24 | $13.2M | $118.0M |
股东权益MTUSOFIX
| Q1 26 | $683.0M | — | ||
| Q4 25 | $686.0M | $450.0M | ||
| Q3 25 | $697.7M | $442.5M | ||
| Q2 25 | $690.0M | $458.3M | ||
| Q1 25 | $686.1M | $458.3M | ||
| Q4 24 | $690.5M | $503.1M | ||
| Q3 24 | $712.7M | $525.9M | ||
| Q2 24 | $736.3M | $546.0M |
总资产MTUSOFIX
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $850.6M | ||
| Q3 25 | $1.2B | $832.6M | ||
| Q2 25 | $1.1B | $837.2M | ||
| Q1 25 | $1.1B | $823.1M | ||
| Q4 24 | $1.1B | $893.3M | ||
| Q3 24 | $1.1B | $867.9M | ||
| Q2 24 | $1.1B | $882.0M |
负债/权益比MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | 0.36× | ||
| Q2 25 | 0.00× | 0.34× | ||
| Q1 25 | 0.01× | 0.34× | ||
| Q4 24 | 0.01× | 0.31× | ||
| Q3 24 | 0.02× | 0.23× | ||
| Q2 24 | 0.02× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-1.9M | $27.7M | ||
| Q3 25 | $22.0M | $12.4M | ||
| Q2 25 | $34.8M | $11.6M | ||
| Q1 25 | $-38.9M | $-18.4M | ||
| Q4 24 | $13.9M | $23.7M | ||
| Q3 24 | $-15.3M | $11.7M | ||
| Q2 24 | $8.3M | $9.0M |
自由现金流MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-37.2M | $16.8M | ||
| Q3 25 | $-6.4M | $2.5M | ||
| Q2 25 | $17.0M | $4.5M | ||
| Q1 25 | $-66.4M | $-25.1M | ||
| Q4 24 | $-1.3M | $15.2M | ||
| Q3 24 | $-32.9M | $6.3M | ||
| Q2 24 | $-5.8M | $-360.0K |
自由现金流率MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | -13.9% | 7.6% | ||
| Q3 25 | -2.1% | 1.2% | ||
| Q2 25 | 5.6% | 2.2% | ||
| Q1 25 | -23.7% | -13.0% | ||
| Q4 24 | -0.5% | 7.0% | ||
| Q3 24 | -14.5% | 3.2% | ||
| Q2 24 | -2.0% | -0.2% |
资本支出强度MTUSOFIX
| Q1 26 | 0.0% | — | ||
| Q4 25 | 13.2% | 4.9% | ||
| Q3 25 | 9.3% | 4.8% | ||
| Q2 25 | 5.8% | 3.5% | ||
| Q1 25 | 9.8% | 3.5% | ||
| Q4 24 | 6.3% | 4.0% | ||
| Q3 24 | 7.7% | 2.7% | ||
| Q2 24 | 4.8% | 4.7% |
现金转化率MTUSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.72× | — | ||
| Q2 25 | 9.41× | — | ||
| Q1 25 | -29.92× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.80× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTUS
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
